Literature DB >> 954347

Absolute quinidine bioavailability.

C T Ueda, B J Williamson, B S Dzindzio.   

Abstract

The absolute bioavailability of quinidine was studied in 11 hospitalized patients. A 400-mg dose of quinidine gluconate was administered to each patient by intravenous infusion and as an oral solution. Drug treatments were separated by a 72-hr period. In 8 patients, peak plasma quinidine concentrations were reached in 65 min after the oral dose; in the remaining 3 subjects, peak concentrations were reached later. From the ratio of the total area under the plasma concentration-time curves (AUCoral/AUCir), the absolute bioavailability of quinidine ranged from 44% to 89% (mean, 72). In 8 patients, the ratio of the total amount of quinidine excreted in the urine in 48 hr (AUinfinity oral/AUinfinity ir) indicated that the extent of quinidine bioavailability varied form 47% to 96% (mean, 73). The predicted bioavailability of quindine due to first-pass effects was 76+/-11%. It is concluded that absorption after the oral solution was rapid and that the reduction of quinidine bioavailability was due to first-pass hepatic drug removal.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 954347     DOI: 10.1002/cpt1976203260

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  22 in total

1.  Dose-dependence of the pharmacokinetics of quinidine.

Authors:  P Bolme; U Otto
Journal:  Eur J Clin Pharmacol       Date:  1977-08-17       Impact factor: 2.953

Review 2.  Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance.

Authors:  U Fuhr
Journal:  Drug Saf       Date:  1998-04       Impact factor: 5.606

3.  Pharmacokinetics of quinidine related to plasma protein binding in man.

Authors:  D Fremstad; O G Nilsen; L Storstein; J Amlie; S Jacobsen
Journal:  Eur J Clin Pharmacol       Date:  1979-04-17       Impact factor: 2.953

4.  The second peak in the serum levels curve after oral administration of a slow-release quinidine dosage form: effect of food.

Authors:  J Spénard; G Sirois; M A Gagnon
Journal:  Br J Clin Pharmacol       Date:  1982-05       Impact factor: 4.335

Review 5.  Protein binding and kinetics of drugs in liver diseases.

Authors:  T F Blaschke
Journal:  Clin Pharmacokinet       Date:  1977 Jan-Feb       Impact factor: 6.447

6.  Comparative bioavailability study of three sustained release quinidine formulations.

Authors:  W A Mahon; J S Leeder; M M Brill-Edwards; J Correia; S M MacLeod
Journal:  Clin Pharmacokinet       Date:  1987-08       Impact factor: 6.447

7.  Urinary excretion kinetics of intact quinidine and 3-OH-quinidine after oral administration of a single oral dose of quinidine gluconate in the fasting and non-fasting state.

Authors:  J M St-Onge; G Sirois; M A Gagnon
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1983 Oct-Dec       Impact factor: 2.441

8.  Bioavailability of quinidine in congestive heart failure.

Authors:  C T Ueda; B S Dzindzio
Journal:  Br J Clin Pharmacol       Date:  1981-06       Impact factor: 4.335

Review 9.  Clinical pharmacokinetics of quinidine.

Authors:  H R Ochs; D J Greenblatt; E Woo
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

Review 10.  Poisoning due to class IA antiarrhythmic drugs. Quinidine, procainamide and disopyramide.

Authors:  S Y Kim; N L Benowitz
Journal:  Drug Saf       Date:  1990 Nov-Dec       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.